Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor
umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It may
also stop the patient's immune system from rejecting the donor's stem cells. The donated stem
cells may replace the patient's immune cells and help destroy any remaining cancer cells
(graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
immune response against the body's normal cells. Giving cyclosporine and mycophenolate
mofetil before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well donor umbilical cord blood transplant with
reduced intensity conditioning works in treating patients with advanced hematological cancer
or other disease.